uniQure N.V.
QUREHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeuniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The $2.77B market capitalization puts QURE squarely in mid-cap range for its industry. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding.
Market Cap
$2.77B
Beta
0.90
P/E (TTM)
—
P/E (Fwd)
-13.95
EPS (TTM)
$-3.57
EPS (Fwd)
$-2.89
ROE
-228.2%
ROA
-17.0%
Cash
$586.6M
Total Debt
$545.7M
Free CF
-$103.7M
52W Change
168.5%
Annual Financials
Cash vs Debt
uniQure N.V. holds $586.6M in cash against $545.7M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$103.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -228.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $106.5M (2022) to $16.1M (2025), a 85% decline worth watching.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing QURE's risk profile alongside its fundamentals and technical indicators provides a more complete picture.